<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1193" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1193/" /><meta name="ncbi_pagename" content="Acute Intermittent Porphyria - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Acute Intermittent Porphyria - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Acute Intermittent Porphyria" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2019/12/05" /><meta name="citation_author" content="Sharon D Whatley" /><meta name="citation_author" content="Michael N Badminton" /><meta name="citation_pmid" content="20301372" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1193/" /><meta name="citation_keywords" content="PBGD Deficiency" /><meta name="citation_keywords" content="Porphobilinogen Deaminase Deficiency" /><meta name="citation_keywords" content="Porphobilinogen Deaminase Deficiency" /><meta name="citation_keywords" content="PBGD Deficiency" /><meta name="citation_keywords" content="Porphobilinogen deaminase" /><meta name="citation_keywords" content="HMBS" /><meta name="citation_keywords" content="Acute Intermittent Porphyria" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Acute Intermittent Porphyria" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Sharon D Whatley" /><meta name="DC.Contributor" content="Michael N Badminton" /><meta name="DC.Date" content="2019/12/05" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1193/" /><meta name="description" content="Acute intermittent porphyria (AIP), an autosomal dominant disorder, occurs in heterozygotes for an HMBS pathogenic variant that causes reduced activity of the enzyme porphobilinogen deaminase. AIP is considered &quot;overt&quot; in a heterozygote who was previously or is currently symptomatic; AIP is considered &quot;latent&quot; in a heterozygote who has never had symptoms, and typically has been identified during molecular genetic testing of at-risk family members. Note that GeneReviews does not use the term &quot;carrier&quot; for an individual who is heterozygous for an autosomal dominant pathogenic variant; GeneReviews reserves the term &quot;carrier&quot; for an individual who is heterozygous for an autosomal recessive disorder and thus is not expected to ever develop manifestations of the disorder." /><meta name="og:title" content="Acute Intermittent Porphyria" /><meta name="og:type" content="book" /><meta name="og:description" content="Acute intermittent porphyria (AIP), an autosomal dominant disorder, occurs in heterozygotes for an HMBS pathogenic variant that causes reduced activity of the enzyme porphobilinogen deaminase. AIP is considered &quot;overt&quot; in a heterozygote who was previously or is currently symptomatic; AIP is considered &quot;latent&quot; in a heterozygote who has never had symptoms, and typically has been identified during molecular genetic testing of at-risk family members. Note that GeneReviews does not use the term &quot;carrier&quot; for an individual who is heterozygous for an autosomal dominant pathogenic variant; GeneReviews reserves the term &quot;carrier&quot; for an individual who is heterozygous for an autosomal recessive disorder and thus is not expected to ever develop manifestations of the disorder." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1193/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/aip/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1193/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8B636EE040BEA10000000003240141.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1193_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1193_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/amrf/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/adams-oliver/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1193_"><span class="title" itemprop="name">Acute Intermittent Porphyria</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonyms: PBGD Deficiency, Porphobilinogen Deaminase Deficiency</div><p class="contrib-group"><span itemprop="author">Sharon D Whatley</span>, PhD, FRCPath and <span itemprop="author">Michael N Badminton</span>, PhD, FRCPath.</p><a data-jig="ncbitoggler" href="#__NBK1193_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1193_ai__"><div class="contrib half_rhythm"><span itemprop="author">Sharon D Whatley</span>, PhD, FRCPath<div class="affiliation small">University Hospital of Wales<br />Cardiff, United Kingdom<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ku.shn.selaw@yeltahw.norahs" class="oemail">ku.shn.selaw@yeltahw.norahs</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Michael N Badminton</span>, PhD, FRCPath<div class="affiliation small">Department of Medical Biochemistry<br />University Hospital of Wales<br />Cardiff, United Kingdom<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ku.shn.selaw@notnimdab.ekim" class="oemail">ku.shn.selaw@notnimdab.ekim</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">September 27, 2005</span>; Last Update: <span itemprop="dateModified">December 5, 2019</span>.</p><p><em>Estimated reading time: 27 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="aip.Summary" itemprop="description"><h2 id="_aip_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Acute intermittent porphyria (AIP), an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> disorder, occurs in heterozygotes for an <i>HMBS</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> that causes reduced activity of the enzyme porphobilinogen deaminase. AIP is considered "overt" in a <a class="def" href="/books/n/gene/glossary/def-item/heterozygote/">heterozygote</a> who was previously or is currently symptomatic; AIP is considered "latent" in a heterozygote who has never had symptoms, and typically has been identified during <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of at-risk family members. Note that <i>GeneReviews</i> does not use the term "<a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>" for an individual who is <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for an autosomal dominant pathogenic variant; <i>GeneReviews</i> reserves the term "carrier" for an individual who is heterozygous for an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> disorder and thus is not expected to ever develop manifestations of the disorder.</p><ul><li class="half_rhythm"><div><i>Overt AIP</i> is characterized clinically by life-threatening acute neurovisceral attacks of severe abdominal pain without peritoneal signs, often accompanied by nausea, vomiting, tachycardia, and hypertension. Attacks may be complicated by neurologic findings (mental changes, convulsions, and peripheral neuropathy that may progress to respiratory paralysis), and hyponatremia. Acute attacks, which may be provoked by certain drugs, alcoholic beverages, endocrine factors, calorie restriction, stress, and infections, usually resolve within two weeks. Most individuals with AIP have one or a few attacks; about 3%-8% (mainly women) have recurrent attacks (defined as &#x0003e;3 attacks/year) that may persist for years. Other long-term complications are chronic renal failure, hepatocellular carcinoma (HCC), and hypertension. Attacks, which are very rare before puberty, are more common in women than men.</div></li><li class="half_rhythm"><div><i>Latent AIP.</i> While all individuals <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for an <i>HMBS</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> that predisposes to AIP are at risk of developing overt AIP, most have latent AIP and never have symptoms.</div></li></ul></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of overt AIP in a symptomatic <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is based on detection of increased concentration of porphobilinogen (PBG) in urine on biochemical testing. Molecular genetic testing is not a first-line diagnostic test for probands; detection of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <i>HMBS</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is mainly used in difficult diagnostic situations &#x02013; for example, when the proband is not available for testing.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations</i>: Acute neurovisceral attacks.</p><ul><li class="half_rhythm"><div>Stop medications that can exacerbate AIP; provide adequate caloric intake by intravenous infusion if required (hypotonic dextrose water solutions should be avoided).</div></li><li class="half_rhythm"><div>Treat any intercurrent infections or disease using drugs known to be safe in acute porphyria.</div></li><li class="half_rhythm"><div>Treat pain with opiate analgesia (often in large amounts); support from a pain team may be required.</div></li><li class="half_rhythm"><div>Treat agitation, vomiting, hypertension, and tachycardia using non-porphyrinogenic drugs (those that will not act as triggers for acute porphyria; also known as "safe" drugs).</div></li><li class="half_rhythm"><div>Monitor fluid balance and correct electrolyte disturbances, especially hyponatremia; treat severe hyponatremia with saline infusions, not fluid restriction.</div></li><li class="half_rhythm"><div>Monitor neurologic status carefully and provide respiratory support as needed.</div></li><li class="half_rhythm"><div>Prompt administration of human hemin (panhematin or heme arginate) is the specific treatment of choice to curtail acute neurovisceral attacks and avoid paresis. Patients treated regularly with heme arginate require monitoring of iron status to detect iron overload.</div></li></ul><p>Mild attacks. Manage by symptomatic treatment, increased calorie intake, and fluid replacement.</p><p>Recurrent acute attacks. Manage together with a porphyria specialist; treatment options include ovulation suppression with gonadorelin analogs, regular hematin infusions, or (as a last resort) liver transplantation.</p><p><i>Evaluation of relatives at risk</i>: If the <i>HMBS</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is known in a family, at-risk relatives can benefit from <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> to clarify their genetic status, so that those at increased risk of developing acute attacks of AIP can be identified early and counseled about preventive measures to reduce the risk of acute attacks.</p><p><i>Prevention of primary manifestations</i>: All individuals with latent AIP, the parents of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals, and patients with overt AIP who are in remission should be advised about measures that diminish the risk of acute attacks:</p><ul><li class="half_rhythm"><div>Avoid precipitating factors (unsafe prescribed and illicit drugs, excessive alcohol consumption, smoking, and severe calorie restriction).</div></li><li class="half_rhythm"><div>Adopt safe practices (maintenance of a regular, balanced diet; prompt treatment of infections; and reduction of stress).</div></li></ul><p><i>Surveillance:</i> Individuals who have experienced acute attacks require monitoring of renal function; in some countries annual hepatic imaging to detect HCC is also offered to all individuals with an <i>HMBS</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> after age 50 years (whether or not they have experienced acute attacks).</p><p><i>Therapies Under Investigation:</i> Givosiran (ALN-AS1), an interference RNA that represses ALAS1, has completed Phase I and III clinical trials that showed reduction of 5-aminolevulinic acid and PBG excretion to near normal levels and a reduction in the rate of porphyria attacks when compared to a placebo.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>AIP is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner. Sibs and offspring of individuals with an <i>HMBS</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> are at 50% risk of inheriting the <i>HMBS</i> pathogenic variant; however, because <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> is low, the likelihood of an individual with an inherited <i>HMBS</i> pathogenic variant having an acute attack is small. Once an <i>HMBS</i> variant has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-testing/">preimplantation genetic testing</a> are possible. However, because clinical penetrance is low, the finding of an <i>HMBS</i> pathogenic variant on prenatal testing cannot be used to predict whether an individual will become symptomatic &#x02013; or if they do become symptomatic, the age of onset, severity, or type of symptoms.</p></div></div><div id="aip.Diagnosis"><h2 id="_aip_Diagnosis_">Diagnosis</h2><p>Acute intermittent porphyria (AIP) is caused by a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <i>HMBS</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. AIP is considered <b>overt</b> in a <a class="def" href="/books/n/gene/glossary/def-item/heterozygote/">heterozygote</a> who was previously or is currently symptomatic and <b>latent</b> in a heterozygote who has never had symptoms, and typically has been diagnosed through cascade screening (i.e., <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> for the <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> <i>HMBS</i> pathogenic variant to identify family members who are heterozygous and, therefore, at increased risk for an acute attack). Individuals with latent AIP may be referred to as "carriers" in the medical literature (see <a href="#aip.Nomenclature">Nomenclature</a>).</p><div id="aip.Suggestive_Findings_in_Probands_with"><h3>Suggestive Findings in Probands with Overt AIP</h3><p>Overt AIP should be suspected in individuals with the following clinical findings and family history.</p><p><b>Clinical findings of overt AIP</b></p><ul><li class="half_rhythm"><div>Otherwise unexplained severe, acute abdominal pain without physical signs. The pain, which occasionally may be more severe in the back or thighs, usually requires opiate analgesia. Abdominal pain is present in the vast majority (92%) of acute attacks; atypical presentations are rare [<a class="bk_pop" href="#aip.REF.puy.2010.924">Puy et al 2010</a>, <a class="bk_pop" href="#aip.REF.gouya.2019">Gouya et al 2019</a>]. Note: Clinically indistinguishable acute attacks occur in other acute porphyrias. See <a href="#aip.Differential_Diagnosis">Differential Diagnosis</a>.</div></li><li class="half_rhythm"><div>Nausea, vomiting, constipation, tachycardia, and hypertension are common.</div></li><li class="half_rhythm"><div>Muscle weakness, convulsions, mental changes, and hyponatremia are all features that may be present alone or in combination and that heighten the probability of acute porphyria [<a class="bk_pop" href="#aip.REF.puy.2010.924">Puy et al 2010</a>].</div></li><li class="half_rhythm"><div>The urine may be reddish-brown or red; however, this is not a constant finding, especially if the sample is fresh. The color is enhanced by exposure to air and light and reflects increased urinary concentrations of porphyrins and porphobilins formed from the porphyrin precursor porphobilinogen (PBG).</div></li></ul><p><b>Family history.</b> Consistent with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> inheritance of an acute porphyria. Family history often reveals no other <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family members due to the low <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> of clinical manifestations of AIP that result in a significant proportion of heterozygotes remaining asymptomatic (see <a href="#aip.Penetrance">Penetrance</a>).</p></div><div id="aip.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of overt AIP in a symptomatic <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is based on detection of increased concentration of PBG in urine on biochemical testing. Molecular genetic testing is not a first-line diagnostic test for probands; detection of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <i>HMBS</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> is mainly used in difficult diagnostic situations &#x02013; for example, where the proband is not available for testing.</p><div id="aip.Biochemical_Testing"><h4>Biochemical Testing</h4><p><b>Urinary PBG.</b> Evidence of an increased concentration of PBG in urine, using a specific quantitative assay, is essential to establish an unequivocal diagnosis of acute porphyria in a symptomatic individual. The concentration of PBG in urine is invariably increased in individuals with symptoms of AIP: during an acute attack, PBG concentration is often more than 10-20 times the upper reference limit [<a class="bk_pop" href="#aip.REF.elder.2013.849">Elder et al 2013</a>].</p><p>PBG is best analyzed in a fresh random 10-mL urine sample collected without preservative, and protected from prolonged exposure to bright light [<a class="bk_pop" href="#aip.REF.woolf.2017.188">Woolf et al 2017</a>]. Urgent testing in new patients will typically require specific arrangements to be made with the biochemistry laboratory but results should be available within 24 hours of sample receipt.</p><p>Note that positive results on qualitative or semi-quantitative urine PBG tests <b>must</b> be confirmed by a specific quantitative measurement to avoid reporting of false positive test results.</p><p><b>Biochemical confirmation</b> that the increased urinary PBG is caused by AIP requires evidence that:</p><ul><li class="half_rhythm"><div>Total fecal porphyrin concentration or coproporphyrin isomer ratio is normal;</div></li><li class="half_rhythm"><div>Plasma porphyrin fluorescence emission scan either shows a peak around 620 nm or is normal.</div></li></ul></div><div id="aip.Molecular_Genetic_Testing"><h4>Molecular Genetic Testing</h4><p><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Molecular genetic testing is not a first-line test for AIP because the relatively high prevalence of <i>HMBS</i> pathogenic variants in the general population (1:1299) and low <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> (0.5%-1%) can lead to misdiagnosis and inappropriate treatment of individuals with nonspecific symptoms of abdominal pain [<a class="bk_pop" href="#aip.REF.chen.2019">Chen et al 2019</a>].</p><p>Following biochemical confirmation of increased urinary PBG, <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> of <i>HMBS</i> is performed first to detect small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants. Note: Depending on the method used, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications may not be detected. If no variant is detected by a sequencing method that is not able to detect exon or whole-gene deletions/duplications, the next step is to perform gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> to detect intragenic deletions or duplications.</p><div id="aip.T.molecular_genetic_testing_used_in" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Acute Intermittent Porphyria</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1193/table/aip.T.molecular_genetic_testing_used_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__aip.T.molecular_genetic_testing_used_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_aip.T.molecular_genetic_testing_used_in_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_aip.T.molecular_genetic_testing_used_in_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Method</th><th id="hd_h_aip.T.molecular_genetic_testing_used_in_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with a Pathogenic Variant&#x000a0;<sup>2</sup> Detectable by Method</th></tr></thead><tbody><tr><td headers="hd_h_aip.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>HMBS</i></td><td headers="hd_h_aip.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></td><td headers="hd_h_aip.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">96%-98%&#x000a0;<sup>4</sup></td></tr><tr><td headers="hd_h_aip.T.molecular_genetic_testing_used_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>5</sup></td><td headers="hd_h_aip.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~2%&#x000a0;<sup>4</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="aip.TF.1.1"><p class="no_margin">See <a href="/books/NBK1193/#aip.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="aip.TF.1.2"><p class="no_margin">See <a href="#aip.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="aip.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="aip.TF.1.4"><p class="no_margin">In individuals with a proven biochemical diagnosis of AIP, <a class="bk_pop" href="#aip.REF.whatley.2009.1406">Whatley et al [2009]</a> reported that of 265 individuals, 255 had a variant detected by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, five had a variant detected by <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and five no variant was detected. <a class="bk_pop" href="#aip.REF.cerbino.2015.946387">Cerbino et al [2015]</a> in a similar study reported that of 107 families, 105 had a variant detected by sequence analysis and two had a variant detected by gene-targeted deletion/duplication analysis.</p></div></dd><dt>5. </dt><dd><div id="aip.TF.1.5"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd></dl></div></div></div></div></div></div><div id="aip.Clinical_Characteristics"><h2 id="_aip_Clinical_Characteristics_">Clinical Characteristics</h2><div id="aip.Clinical_Description"><h3>Clinical Description</h3><p>Acute intermittent porphyria (AIP), caused by a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <i>HMBS</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, is considered <b>overt</b> when a <a class="def" href="/books/n/gene/glossary/def-item/heterozygote/">heterozygote</a> was previously or is currently symptomatic and <b>latent</b> when a heterozygote has never had symptoms, and typically has been diagnosed through cascade screening (i.e., <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> for the <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> <i>HMBS</i> pathogenic variant to identify family members who are heterozygous and therefore at increased risk for an acute attack).</p><div id="aip.Overt_AIP"><h4>Overt AIP</h4><p>Symptoms of AIP are more common in women than men and very rare before puberty. Onset typically occurs in the third or fourth decade [<a class="bk_pop" href="#aip.REF.elder.2013.849">Elder et al 2013</a>, <a class="bk_pop" href="#aip.REF.bonkovsky.2014.1233">Bonkovsky et al 2014</a>].</p><p>The visceral, peripheral, autonomic, and/or central nervous systems may be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, leading to a range of findings that are usually intermittent and sometimes life threatening. The course of acute attacks is highly variable within and between individuals.</p><p>Affected individuals may recover from acute AIP attacks within days, but recovery from severe attacks that are not promptly recognized and treated may take weeks or months. Although attacks in most individuals are typically caused by exposure to certain endogenous or exogenous factors, it is not uncommon for individuals to have acute attacks in which no precipitating factor can be identified.</p><p><b>Acute attack.</b> Severe abdominal pain, which may be generalized or localized and not accompanied by muscle guarding, is the most common symptom and is often the initial sign of an acute attack. Back, buttock, or limb pain may be a feature. Gastrointestinal features including nausea, vomiting, constipation or diarrhea, abdominal distention, and ileus are also common. Tachycardia and hypertension are frequent, while fever, sweating, restlessness, and tremor are seen less frequently. Urinary retention, incontinence, and dysuria may be present.</p><p><b>Peripheral neuropathy</b> is predominantly motor and is less common now than in the past. Muscle weakness often begins proximally in the legs but may involve the arms or legs distally and can progress to include respiratory muscles resulting in complete paralysis with respiratory failure. Bilateral axonal motor neuropathy may also involve the distal radial nerves. Motor neuropathy may also affect the cranial nerves or lead to bulbar paralysis.</p><p>Patchy sensory neuropathy may also occur</p><p><b>Mental changes</b> are present in up to 30% of symptomatic individuals but are very rarely the dominant feature of AIP [<a class="bk_pop" href="#aip.REF.puy.2010.924">Puy et al 2010</a>]. Changes include insomnia, anxiety, depression, hallucinations, confusion, paranoia, amnesia, and/or altered consciousness ranging from somnolence to coma. These manifestations resolve after the attack, though anxiety may persist.</p><p><b>Seizures</b> may occur in acute attacks, especially in individuals with hyponatremia, which may be worsened by vomiting and/or inappropriate fluid therapy. The cause of hyponatremia is not clear; both SIADH (syndrome of inappropriate antidiuretic hormone release) and renal salt wasting have been proposed as mechanisms.</p><p>Seizures may also be a manifestation of central nervous system involvement of the acute attack.</p><p><b>MRI findings.</b> MRI changes were observed in two out of seven individuals with signs of CNS involvement. The main finding is posterior reversible encephalopathy syndrome [<a class="bk_pop" href="#aip.REF.pischik.2009.72">Pischik &#x00026; Kauppinen 2009</a>]. Twenty-two individuals with AIP presenting with posterior reversible encephalopathy syndrome were investigated with MRI imaging [<a class="bk_pop" href="#aip.REF.zheng.2018.e11665">Zheng et al 2018</a>]; 95% of these presented with seizures that may be related to hyponatremia.</p><p><b>Cutaneous manifestations of porphyria</b> do not occur in AIP.</p><p><b>Precipitating factors.</b> Attacks of acute porphyria may be precipitated by endogenous or exogenous factors [<a class="bk_pop" href="#aip.REF.wang.2018.193">Wang et al 2018</a>]. These include:</p><ul><li class="half_rhythm"><div><b>Prescribed and illicit drugs</b> that are detoxified in the liver by cytochrome P450 and/or result in induction of 5-aminolevulinic acid (ALA) synthase and heme biosynthesis. Prescription drugs that can precipitate an attack include, for example, barbiturates, sulfa-containing antibiotics, some antiepileptic drugs, progestagens, and synthetic estrogens (see <a href="#aip.AgentsCircumstances_to_Avoid_for_All">Agents/Circumstances to Avoid</a>).</div></li><li class="half_rhythm"><div><b>Endocrine factors.</b> Reproductive hormones play an important role in the clinical expression of AIP. In women, acute neurovisceral attacks related to the menstrual cycle, usually the luteal phase, are common [<a class="bk_pop" href="#aip.REF.wang.2018.193">Wang et al 2018</a>]. However, the majority of women with AIP fare well during pregnancy, despite substantial increases in the serum concentration of various steroid hormones [<a class="bk_pop" href="#aip.REF.marsden.2010.591">Marsden &#x00026; Rees 2010</a>].</div></li><li class="half_rhythm"><div><b>Fasting.</b> A recognized precipitating factor is inadequate caloric intake [<a class="bk_pop" href="#aip.REF.wang.2018.193">Wang et al 2018</a>] in connection with, for example, dieting or heavy exercise schedules.</div></li><li class="half_rhythm"><div><b>Stress.</b> Psychosocial and other stresses, including intercurrent illnesses, infections, alcoholic excess, and surgery, can precipitate an attack.</div></li></ul><p><b>Chronic complications</b></p><ul><li class="half_rhythm"><div><b>Hepatocellular carcinoma (HCC).</b> Individuals with AIP, whether clinically manifest or latent, appear to be at increased risk of developing primary HCC [<a class="bk_pop" href="#aip.REF.innala.2011.538">Innala &#x00026; Andersson 2011</a>], usually after age 54 years. The highest risk has been reported from Sweden; at present, it is unclear why the risk appears to be lower in other populations [<a class="bk_pop" href="#aip.REF.deybach.2011.521">Deybach &#x00026; Puy 2011</a>, <a class="bk_pop" href="#aip.REF.elder.2013.849">Elder et al 2013</a>]. The increased incidence of HCC appears to justify radiologic surveillance in individuals with AIP over age 50 years in order to allow early detection and improve outcomes [<a class="bk_pop" href="#aip.REF.peoch.2018">Peoc'h et al 2018</a>].</div></li><li class="half_rhythm"><div><b>Renal involvement.</b> Approximately 70% of individuals with recurrent attacks will develop progressive renal dysfunction as shown by declining estimated glomerular filtration rate (eGFR) (&#x0003c;90 mL/min/1.73m<sup>2</sup>). This may be a result of chronic renal exposure to high concentrations of ALA and porphobilinogen (PBG), influenced by genetic variation in the ALA transporter PEP2 [<a class="bk_pop" href="#aip.REF.tchernitchko.2017.1924">Tchernitchko et al 2017</a>].</div></li><li class="half_rhythm"><div><b>Recurrent acute attacks.</b> Approximately 3%-8% of individuals with AIP, mainly women, experience repeat attacks (defined as &#x0003e;3/yr in the EXPLORE study) for a prolonged period, often many years [<a class="bk_pop" href="#aip.REF.gouya.2019">Gouya et al 2019</a>].</div></li></ul><p><b>Mortality.</b> Mortality directly related to acute attacks is now very rare in most countries as a result of improved treatment (use of human hemin; see Management, <a href="#aip.Treatment_of_Manifestations_of_Overt">Treatment of Manifestations</a>) and identification and counseling of presymptomatic relatives (see Management, <a href="#aip.Evaluation_of_Relatives_at_Risk_for">Evaluation of Relatives at Risk</a>). Deaths may occur as a complication of HCC or liver transplantation.</p></div><div id="aip.Latent_AIP"><h4>Latent AIP</h4><p>Symptoms are present in only a minority of those <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for an <i>HMBS</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> that predisposes to AIP, and it may be difficult to be certain whether or not these are porphyria-related. The risk that an individual with latent AIP will later develop symptoms depends on age, sex, exposure to provoking agents, and other factors; however, the majority will remain asymptomatic throughout their lives.</p><p>Up to 50% of adults with latent AIP may have increased urinary PBG excretion.</p></div></div><div id="aip.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>Genotype-<a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> correlations are not evident in AIP.</p></div><div id="aip.Penetrance"><h3>Penetrance</h3><p>Families from the French reference center for porphyria were evaluated for <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> of AIP. The cohort consisted of 496 symptomatic individuals and 1672 asymptomatic relatives with an <i>HMBS</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. The estimated penetrance of AIP in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> families was 22.9% and 12.7% in the relatives of AIP index cases.</p><p>Using <a href="https://evs.gs.washington.edu/EVS/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Exome Variant Server</a> data, a minimal prevalence of <i>HMBS</i> pathogenic variants in the general population was calculated as 1:1299. In France the prevalence of pathogenic variants in the general population was estimated at between 50-100,000 individuals and the prevalence 0.5%-1%. The authors propose that <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> is a consequence of both environmental and genetic factors [<a class="bk_pop" href="#aip.REF.lenglet.2018.1164">Lenglet et al 2018</a>].</p></div><div id="aip.Nomenclature"><h3>Nomenclature</h3><p>Individuals with latent AIP are often referred to as "carriers" in the medical literature. <i>GeneReviews</i> does not use the term "carrier" for an individual who is <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> &#x02013; reserving the term "carriers" for those who are heterozygous for an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> disorder, and thus are not expected to ever develop manifestations of the disorder.</p><p>Overt AIP may also be referred to as "manifest AIP."</p></div><div id="aip.Prevalence"><h3>Prevalence</h3><p>In most countries, AIP is the most common of the acute hepatic porphyrias [<a class="bk_pop" href="#aip.REF.wang.2018.193">Wang et al 2018</a>].</p><ul><li class="half_rhythm"><div>The prevalence of overt AIP in France is 1:132 000 inhabitants [<a class="bk_pop" href="#aip.REF.lenglet.2018.1164">Lenglet et al 2018</a>]. This is similar to the incidence of newly diagnosed individuals in Europe, excluding Sweden, with overt AIP reported as 0.13:1,000,000 per year, with a calculated prevalence of 5.9:1,000,000 [<a class="bk_pop" href="#aip.REF.elder.2013.849">Elder et al 2013</a>].</div></li><li class="half_rhythm"><div>In Sweden the incidence and prevalence of AIP are about four times higher than in Europe due to a <a class="def" href="/books/n/gene/glossary/def-item/founder-effect/">founder effect</a> originating in Lappland [<a class="bk_pop" href="#aip.REF.floderus.2002.288">Floderus et al 2002</a>] (see <a class="figpopup" href="/books/NBK1193/table/aip.T.notable_hmbs_pathogenic_variants/?report=objectonly" target="object" rid-figpopup="figaipTnotablehmbspathogenicvariants" rid-ob="figobaipTnotablehmbspathogenicvariants">Table 3. Notable <i>HMBS</i> Pathogenic Variants</a>).</div></li></ul></div></div><div id="aip.Genetically_Related_Allelic_Disorder"><h2 id="_aip_Genetically_Related_Allelic_Disorder_">Genetically Related (Allelic) Disorders</h2><p>To date, six children with <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> or <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a> <i>HMBS</i> pathogenic variants have been described.</p><ul><li class="half_rhythm"><div>Four had pathogenic variants in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 9 (<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000190.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000190.3</a>). Manifestations starting early in childhood included severe ataxia, dysarthria, severe psychomotor delay, and central and peripheral neurologic manifestations. MRI studies in one showed white matter abnormalities that suggested selective postnatal involvement of cerebral oligodendrocytes [<a class="bk_pop" href="#aip.REF.solis.2004.1764">Solis et al 2004</a>].</div></li><li class="half_rhythm"><div>One, who was a compound <a class="def" href="/books/n/gene/glossary/def-item/heterozygote/">heterozygote</a> for an <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 9 and exon 3 (NM_000190.3) <i>HMBS</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, presented in infancy with neurologic findings and abnormal CNS imaging [<a class="bk_pop" href="#aip.REF.dixon.2019">Dixon et al 2019</a>].</div></li><li class="half_rhythm"><div>One, who was <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for a <i>HMBS</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 5 (NM_000190.3), was less severely <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> than those described above [<a class="bk_pop" href="#aip.REF.hessels.2004.19">Hessels et al 2004</a>].</div></li></ul></div><div id="aip.Differential_Diagnosis"><h2 id="_aip_Differential_Diagnosis_">Differential Diagnosis</h2><p><b>Acute neurovisceral attacks.</b> Clinically indistinguishable acute neurovisceral attacks occur in acute intermittent porphyria (AIP) and the three other acute porphyrias, and may complicate <a href="/books/n/gene/tyrosinemia/">hereditary tyrosinemia type 1</a> (see <a class="figpopup" href="/books/NBK1193/table/aip.T.genes_of_interest_in_the_different/?report=objectonly" target="object" rid-figpopup="figaipTgenesofinterestinthedifferent" rid-ob="figobaipTgenesofinterestinthedifferent">Table 2</a>) [<a class="bk_pop" href="#aip.REF.puy.2010.924">Puy et al 2010</a>].</p><div id="aip.T.genes_of_interest_in_the_different" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Genes of Interest in the Differential Diagnosis of Clinically Manifest Acute Intermittent Porphyria (AIP)</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1193/table/aip.T.genes_of_interest_in_the_different/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__aip.T.genes_of_interest_in_the_different_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_aip.T.genes_of_interest_in_the_different_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_aip.T.genes_of_interest_in_the_different_1_1_1_1" style="text-align:left;vertical-align:middle;">Gene</th><th id="hd_h_aip.T.genes_of_interest_in_the_different_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_aip.T.genes_of_interest_in_the_different_1_1_1_2" style="text-align:left;vertical-align:middle;">Disorder</th><th id="hd_h_aip.T.genes_of_interest_in_the_different_1_1_1_3" rowspan="2" scope="col" colspan="1" headers="hd_h_aip.T.genes_of_interest_in_the_different_1_1_1_3" style="text-align:left;vertical-align:middle;">MOI</th><th id="hd_h_aip.T.genes_of_interest_in_the_different_1_1_1_4" rowspan="2" scope="col" colspan="1" headers="hd_h_aip.T.genes_of_interest_in_the_different_1_1_1_4" style="text-align:left;vertical-align:middle;">Clinical Features</th><th id="hd_h_aip.T.genes_of_interest_in_the_different_1_1_1_5" colspan="4" scope="colgroup" rowspan="1" style="text-align:center;vertical-align:middle;">Biochemical Characteristics&#x000a0;<sup>1</sup></th></tr><tr><th headers="hd_h_aip.T.genes_of_interest_in_the_different_1_1_1_5" id="hd_h_aip.T.genes_of_interest_in_the_different_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Urine</th><th headers="hd_h_aip.T.genes_of_interest_in_the_different_1_1_1_5" id="hd_h_aip.T.genes_of_interest_in_the_different_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Stool</th><th headers="hd_h_aip.T.genes_of_interest_in_the_different_1_1_1_5" id="hd_h_aip.T.genes_of_interest_in_the_different_1_1_2_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Plasma</th><th headers="hd_h_aip.T.genes_of_interest_in_the_different_1_1_1_5" id="hd_h_aip.T.genes_of_interest_in_the_different_1_1_2_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Erythrocytes</th></tr></thead><tbody><tr><td headers="hd_h_aip.T.genes_of_interest_in_the_different_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>CPOX</i></td><td headers="hd_h_aip.T.genes_of_interest_in_the_different_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/hcp/">Hereditary coproporphyria</a> (HCP)</td><td headers="hd_h_aip.T.genes_of_interest_in_the_different_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_aip.T.genes_of_interest_in_the_different_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Acute attack &#x000b1; skin lesions&#x000a0;<sup>2</sup></td><td headers="hd_h_aip.T.genes_of_interest_in_the_different_1_1_1_5 hd_h_aip.T.genes_of_interest_in_the_different_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02191; PBG, ALA&#x000a0;<sup>3</sup>, porphyrins&#x000a0;<sup>4</sup></td><td headers="hd_h_aip.T.genes_of_interest_in_the_different_1_1_1_5 hd_h_aip.T.genes_of_interest_in_the_different_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02191; copro-<br />porphyrin III</td><td headers="hd_h_aip.T.genes_of_interest_in_the_different_1_1_1_5 hd_h_aip.T.genes_of_interest_in_the_different_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02191; plasma porphyrins; fluorescence emission peak ~620 nm&#x000a0;<sup>5</sup></td><td headers="hd_h_aip.T.genes_of_interest_in_the_different_1_1_1_5 hd_h_aip.T.genes_of_interest_in_the_different_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_aip.T.genes_of_interest_in_the_different_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>PPOX</i></td><td headers="hd_h_aip.T.genes_of_interest_in_the_different_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/porphyria-var/">Variegate porphyria</a> (VP)</td><td headers="hd_h_aip.T.genes_of_interest_in_the_different_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_aip.T.genes_of_interest_in_the_different_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Acute attack &#x000b1; skin lesions&#x000a0;<sup>2</sup></td><td headers="hd_h_aip.T.genes_of_interest_in_the_different_1_1_1_5 hd_h_aip.T.genes_of_interest_in_the_different_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02191; PBG, ALA&#x000a0;<sup>3</sup>, porphyrins&#x000a0;<sup>4</sup></td><td headers="hd_h_aip.T.genes_of_interest_in_the_different_1_1_1_5 hd_h_aip.T.genes_of_interest_in_the_different_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02191; proto-<br />porphyrin&#x000a0;<sup>6</sup></td><td headers="hd_h_aip.T.genes_of_interest_in_the_different_1_1_1_5 hd_h_aip.T.genes_of_interest_in_the_different_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02191; plasma porphyrins; fluorescence emission peak ~626 nm&#x000a0;<sup>7</sup></td><td headers="hd_h_aip.T.genes_of_interest_in_the_different_1_1_1_5 hd_h_aip.T.genes_of_interest_in_the_different_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_aip.T.genes_of_interest_in_the_different_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ALAD</i></td><td headers="hd_h_aip.T.genes_of_interest_in_the_different_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">ALAD deficiency porphyria<br />(OMIM <a href="https://omim.org/entry/612740" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">612740</a>)</td><td headers="hd_h_aip.T.genes_of_interest_in_the_different_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_aip.T.genes_of_interest_in_the_different_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Acute attack</td><td headers="hd_h_aip.T.genes_of_interest_in_the_different_1_1_1_5 hd_h_aip.T.genes_of_interest_in_the_different_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02191; ALA, copropor-<br />phyrin III, normal PBG</td><td headers="hd_h_aip.T.genes_of_interest_in_the_different_1_1_1_5 hd_h_aip.T.genes_of_interest_in_the_different_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_aip.T.genes_of_interest_in_the_different_1_1_1_5 hd_h_aip.T.genes_of_interest_in_the_different_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_aip.T.genes_of_interest_in_the_different_1_1_1_5 hd_h_aip.T.genes_of_interest_in_the_different_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02191; zinc-protoporphyrin; &#x02193; ALAD activity</td></tr><tr><td headers="hd_h_aip.T.genes_of_interest_in_the_different_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>FAH</i></td><td headers="hd_h_aip.T.genes_of_interest_in_the_different_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/tyrosinemia/">Tyrosinemia type 1</a></td><td headers="hd_h_aip.T.genes_of_interest_in_the_different_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_aip.T.genes_of_interest_in_the_different_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Acute attack</td><td headers="hd_h_aip.T.genes_of_interest_in_the_different_1_1_1_5 hd_h_aip.T.genes_of_interest_in_the_different_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02191; ALA</td><td headers="hd_h_aip.T.genes_of_interest_in_the_different_1_1_1_5 hd_h_aip.T.genes_of_interest_in_the_different_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_aip.T.genes_of_interest_in_the_different_1_1_1_5 hd_h_aip.T.genes_of_interest_in_the_different_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_aip.T.genes_of_interest_in_the_different_1_1_1_5 hd_h_aip.T.genes_of_interest_in_the_different_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02193; ALAD activity</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">AD = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>; ALA = 5-aminolevulinic acid; ALAD = 5-aminolevulinate dehydratase; AR = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>; MOI = <a class="def" href="/books/n/gene/glossary/def-item/mode-of-inheritance/">mode of inheritance</a></p></div></dd><dt>1. </dt><dd><div id="aip.TF.2.1"><p class="no_margin">See <a class="figpopup" href="/books/NBK1193/table/aip.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figaipTmoleculargenetictestingusedin" rid-ob="figobaipTmoleculargenetictestingusedin">Table 1</a> for biochemical characteristics of clinically manifest AIP.</p></div></dd><dt>2. </dt><dd><div id="aip.TF.2.2"><p class="no_margin">Acute neurovisceral attacks are accompanied by porphyric skin lesions (bullae, fragile skin) in about 15% of persons with HCP and about 60% of persons with VP.</p></div></dd><dt>3. </dt><dd><div id="aip.TF.2.3"><p class="no_margin">PBG increased more than ALA; both may decrease rapidly as symptoms resolve.</p></div></dd><dt>4. </dt><dd><div id="aip.TF.2.4"><p class="no_margin">Uroporphyrin from <i>in vitro</i> polymerization of PBG and coproporphyrin; measurement is not required for diagnosis and may mislead.</p></div></dd><dt>5. </dt><dd><div id="aip.TF.2.5"><p class="no_margin">Plasma porphyrin concentration may occasionally be normal; fluorescence emission spectroscopy does not distinguish between HCP and AIP.</p></div></dd><dt>6. </dt><dd><div id="aip.TF.2.6"><p class="no_margin">Protoporphyrin is the main stool porphyrin, but a small increase in coproporphyrin III is also observed</p></div></dd><dt>7. </dt><dd><div id="aip.TF.2.7"><p class="no_margin">Plasma porphyrin concentration is always increased and fluorescence emission spectroscopy distinguishes VP from all other porphyrias.</p></div></dd></dl></div></div></div><p><b>Lead poisoning</b> may also mimic the symptoms (i.e., abdominal pain) of clinically manifest acute AIP and disturb heme biosynthesis; however, anemia, a feature of lead poisoning, is not a feature of AIP. Lead poisoning is characterized in urine by increased 5-aminolevulinic acid (ALA), coproporphyrin III, normal porphobilinogen and in erythrocytes, increased zinc-protoporphyrin and decreased 5-aminolevulinate dehydratase (ALAD) activity.</p><p><b>Red discoloration of the urine.</b> Hematuria, ingestion of beetroot, some drugs and food additives, and porphyrin excretion in other porphyrias (e.g., <a href="/books/n/gene/porphyria-ct/">porphyria cutanea tarda</a>, <a href="/books/n/gene/cep/">congenital erythropoietic porphyria</a>) may produce similar red discoloration of the urine.</p><p>Note: For a general review of the genetic porphyrias, see <a href="/books/n/gene/hcp/">Hereditary Coproporphyria</a><b>,</b> Differential Diagnosis.</p></div><div id="aip.Management"><h2 id="_aip_Management_">Management</h2><p><b>Evaluations Following Initial Diagnosis of Latent AIP and Asymptomatic Individuals with a History of Overt AIP</b></p><p>To establish the extent of disease and needs in an individual diagnosed with acute intermittent porphyria, the following evaluations (if not performed as part of the evaluation that led to the diagnosis) are recommended:</p><ul><li class="half_rhythm"><div>Full clinical history and examination, including neurologic evaluation</div></li><li class="half_rhythm"><div>Review of medications to assess risk versus benefit (see <a href="#aip.AgentsCircumstances_to_Avoid_for_All">Agents/Circumstances to Avoid</a>)</div></li><li class="half_rhythm"><div>Quantitation of urine porphobilinogen (PBG) excretion to establish a baseline for comparison with future measurements taken during symptoms suggestive of active porphyria</div></li><li class="half_rhythm"><div>Patients should be advised to register with an organization that provides warning jewelry in case of an accident (e.g., MedicAlert<sup>&#x000ae;</sup> or similar).</div></li><li class="half_rhythm"><div>Referral to a porphyria specialist for more detailed clinical advice on AIP (see <a href="#aip.Resources">Resources</a>)</div></li><li class="half_rhythm"><div>Patients should be advised about support from national patient associations where available. Good-quality information is now widely available from patient or professional organizations either in paper form or from the Internet; see <a href="#aip.Resources">Resources</a>.</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul><div id="aip.Treatment_of_Manifestations_of_Overt"><h3>Treatment of Manifestations of Overt AIP</h3><div id="aip.Acute_Neurovisceral_Attack"><h4>Acute Neurovisceral Attack</h4><p>Immediate treatment of an acute neurovisceral attack does not require confirmation of the specific type of acute porphyria.</p><p>Clinical assessment should include a full neurologic evaluation.</p><p>In persons known to have AIP consider other causes of abdominal pain in addition to porphyria.</p><p>Investigations should include the following:</p><ul><li class="half_rhythm"><div>Full blood count</div></li><li class="half_rhythm"><div>Measurement of serum/plasma concentrations of urea, creatinine, and electrolytes</div></li><li class="half_rhythm"><div>Serum and urine osmolality if hyponatremic</div></li><li class="half_rhythm"><div>Urine sodium concentration if hyponatremic</div></li><li class="half_rhythm"><div>Other blood tests as indicated by the patient's condition and possible cause of the attack (e.g., CRP, blood cultures, CK, magnesium)</div></li></ul><p>MRI should be considered if CNS symptoms are present.</p><p><b>General measures</b></p><ul><li class="half_rhythm"><div>Review all medications and discontinue any that can exacerbate acute porphyria [<a class="bk_pop" href="#aip.REF.stein.2017.527">Stein et al 2017</a>]. See <a href="#aip.AgentsCircumstances_to_Avoid_for_All">Agents/Circumstances to Avoid</a>.</div></li><li class="half_rhythm"><div>Restore energy balance using an enteral route if possible. When required, intravenous fluid should contain a minimum of 5% dextrose; however, hypotonic dextrose-water solutions should be avoided because of the risk of hyponatremia.</div></li><li class="half_rhythm"><div>Treat intercurrent infections and other diseases promptly.</div></li></ul><p><b>Supportive treatment</b></p><ul><li class="half_rhythm"><div><b>Pain relief.</b> Effective analgesia should be provided as soon as possible, usually in the form of parenteral opiates (morphine, diamorphine, and fentanyl are safe). Very large quantities may be required in a severe acute attack. Consider patient-controlled analgesia and support from a pain team.</div></li><li class="half_rhythm"><div><b>Nausea and vomiting.</b> Prochloperazine, promazine, or ondansetron are considered safe.</div></li><li class="half_rhythm"><div><b>Hypertension.</b> Beta blockers are considered safe. Note: End-stage renal disease, which is thought to result from chronic systemic arterial hypertension, may be delayed through effective blood pressure control [<a class="bk_pop" href="#aip.REF.stewart.2012.976">Stewart 2012</a>].</div></li><li class="half_rhythm"><div><b>Convulsions</b> can be terminated with intravenous diazepam, clonazepam, or magnesium sulphate.</div></li><li class="half_rhythm"><div><b>Fluid balance and electrolytes.</b> Intravenous fluid replacement may be required to correct dehydration or electrolyte imbalance. Dextrose in water solutions should be avoided because of the risk of hyponatremia. Chronic hyponatremia (developing over &#x0003e;48 hours) should be corrected slowly to minimize the risk of central pontine myelinolysis [<a class="bk_pop" href="#aip.REF.stein.2017.527">Stein et al 2017</a>].</div></li></ul><p><b>Specific treatment</b></p><ul><li class="half_rhythm"><div>For mild acute neurovisceral attacks, a high carbohydrate intake, preferably oral and together with other supportive measures (see <a href="#aip.Acute_Neurovisceral_Attack">Acute Neurovisceral Attack</a>), may be used for up to 48 hours. If improvement is unsatisfactory or if additional and progressive neurologic features present, intravenous administration of hemin preparations is recommended.</div></li><li class="half_rhythm"><div>Intravenous human hemin is the most effective treatment for acute neurovisceral attacks. Intravenous administration of hemin preparations may be life saving if employed early, when neuronal damage is still reversible, and may help to avoid paresis or prevent its progression.</div><ul><li class="half_rhythm"><div>The recommended dose for hemin is 3-4 mg/kg IV, given once daily for four days. Treatment may be extended, depending on the clinical course. Note: Because 100 mg of hemin contains 8 mg of iron, frequent administration of hemin may increase the risk for iron overload. Periodic monitoring of serum ferritin concentration and/or transferrin saturation is therefore appropriate in individuals treated repeatedly with hemin.</div></li><li class="half_rhythm"><div>Panhematin&#x02122; (Ovation Pharmaceuticals, Inc) is approved for treatment of acute attacks in the US. This product is supplied as a dried powder, which must be reconstituted with sterile water immediately before intravenous injection and administered over 10-15 minutes. Because the administration of Panhematin&#x02122; reconstituted with sterile water is associated with transient, mild coagulopathy, concurrent anticoagulant therapy should be avoided.</div></li><li class="half_rhythm"><div>Heme arginate (Normosang Recordati Rare Diseases, Paris) is an arginine-stabilized form of human hemin available nearly worldwide, including in Europe, Africa, the Middle East, and South America. It is infused over at least 30 minutes. It has the same advantage as hemin in treating an acute neurovisceral attack, but has fewer reported side effects [<a class="bk_pop" href="#aip.REF.puy.2010.924">Puy et al 2010</a>].</div></li></ul></li></ul><p>Note: (1) Phlebitis after intravenous injection can be minimized by reconstituting hematin in 20% human serum albumin solution and/or by using a large vein or a central catheter for infusion. Peripheral cannulas used to administer hematin should be replaced after each use. (2) An infusion set with an in-line filter is recommended to remove any undissolved particulate matter. (3) Rigorous flushing of venous catheters with boluses of saline totaling 100 mL is recommended.</p><p>Advice on safe treatment of persons with porphyria in some specific clinical situations (e.g., epilepsy, HIV, malaria, tuberculosis, hyperlipidemia, and hypertension) is available on the <a href="http://www.porphyria.uct.ac.za" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Porphyria South Africa</a> website.</p></div><div id="aip.Recurrent_Acute_Attacks"><h4>Recurrent Acute Attacks</h4><p>Recurrent acute attacks are best managed with support and advice from a porphyria specialist. See information and contact details of specialist porphyria centers at the <a href="http://porphyria.eu/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">European Porphyria Network</a> website.</p><p>Medical therapy aims to reduce the frequency and or severity of acute attacks by the following measures:</p><ul><li class="half_rhythm"><div>Ovulation suppression with gonadorelin analogs for patients with recurrent menstrual cycle-related acute neurovisceral attacks [<a class="bk_pop" href="#aip.REF.schulenburgbrand.2017.99">Schulenburg-Brand et al 2017</a>]. Long-acting analogs can be used to prevent ovulation and should be administered during the first few days of the menstrual cycle to minimize the early stimulation effect on hormone release which can trigger an attack. Side effects can be minimized by administering estrogen, preferably by patch. Gynecologic review and bone density monitoring are recommended.</div></li><li class="half_rhythm"><div>Prophylactic hemin infusion. The minimum effective infusion frequency should be employed, usually a weekly dose of hemin infused via an indwelling venous catheter. Problems include those associated with a venous access device (infection, blockage) and iron overload (see <a href="#aip.Prevention_of_Primary_Manifestations">Prevention of Primary Manifestations</a>).</div></li><li class="half_rhythm"><div>Givosiran (ALN-AS1), an interference RNA that represses ALAS1, has completed Phase I and III clinical trials and was approved by the US Food and Drug Administration (FDA) in November 2019. The trial showed a reduction of ALA and PBG excretion to near normal levels and a reduction in the rate of porphyria attacks when compared to a placebo. Adverse events included elevated liver enzymes and chronic kidney disease [<a class="bk_pop" href="#aip.REF.sardh.2019.549">Sardh et al 2019</a>].</div></li></ul></div><div id="aip.Other_Treatments"><h4>Other Treatments</h4><p>Liver transplantation is curative and reported from several centers [<a class="bk_pop" href="#aip.REF.wahlin.2010.e18">Wahlin et al 2010</a>]. Indications include repeated life-threatening acute attacks, failure of medical therapy, and poor quality of life.</p><p>Combined liver and kidney transplantation, which has been successful, can be considered in those with AIP with repeated severe attacks and renal failure [<a class="bk_pop" href="#aip.REF.wahlin.2010.e18">Wahlin et al 2010</a>]. Patients with AIP may require dialysis or renal transplantation [<a class="bk_pop" href="#aip.REF.wang.2018.193">Wang et al 2018</a>].</p></div></div><div id="aip.Prevention_of_Primary_Manifestations"><h3>Prevention of Primary Manifestations for all Individuals with AIP</h3><p>To prevent acute attacks patients are advised on the potential triggers as follows:</p><ul><li class="half_rhythm"><div>Assure that adequate nutrition is provided by a normal balanced diet. Avoid unsupervised calorie restriction diets, particularly those that exclude carbohydrate completely.</div></li><li class="half_rhythm"><div>Avoid drugs and chemicals known to exacerbate porphyria, particularly prescribed medication and over-the-counter medication. See <a href="#aip.AgentsCircumstances_to_Avoid_for_All">Agents/Circumstances to Avoid</a>.</div></li><li class="half_rhythm"><div>Seek timely treatment of systemic illness or infection.</div></li><li class="half_rhythm"><div>Avoid excessive alcohol consumption and smoking.</div></li></ul></div><div id="aip.Surveillance"><h3>Surveillance</h3><div id="aip.Individuals_with_Overt_AIP"><h4>Individuals with Overt AIP</h4><p>Annual hepatic imaging for HCC in individuals older than age 50 years has been shown to improve survival [<a class="bk_pop" href="#aip.REF.innala.2011.538">Innala &#x00026; Andersson 2011</a>]. The incidence of HCC in this group of patients with AIP is 0.6% and it has been recommended in Europe that imaging should probably be biannual to bring it in line with other liver diseases that infer an increased risk for HCC [<a class="bk_pop" href="#aip.REF.peoch.2018">Peoc'h et al 2018</a>].</p><p>Note: (1) Serum &#x003b1;-fetoprotein measurement is not helpful. (2) Protein induced by Vitamin K absence (PIVKA-II) may be useful as a biomarker [<a class="bk_pop" href="#aip.REF.peoch.2018">Peoc'h et al 2018</a>].</p></div></div><div id="aip.Individuals_with_Latent_AIP"><h3>Individuals with Latent AIP</h3><p><a class="bk_pop" href="#aip.REF.peoch.2018">Peoc'h et al [2018]</a> reviewed five published studies that reported 77 individuals with acute hepatic porphyria (AHP) diagnosed with primary liver cancer. The proportion of patients with latent AHP varied between 0 and 43%.</p></div><div id="aip.AgentsCircumstances_to_Avoid_for_All"><h3>Agents/Circumstances to Avoid for All Individuals with AIP</h3><p>Excessive alcohol consumption and smoking should be avoided.</p><p>Knowledge about the safety of many drugs and other over-the-counter preparations in acute porphyrias is incomplete; however, evidence-based guidelines for assessment of drug porphyrogenicity have been published [<a class="bk_pop" href="#aip.REF.hift.2011.158">Hift et al 2011</a>].</p><ul><li class="half_rhythm"><div>Searchable drug safety databases are available at the following websites:</div><ul><li class="half_rhythm"><div><a href="http://www.drugs-porphyria.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">The Drug Database for Acute Porphyria</a></div></li><li class="half_rhythm"><div><a href="http://www.porphyriafoundation.com/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">The American Porphyria Foundation</a></div></li></ul></li><li class="half_rhythm"><div>Information on prescribing in certain conditions (e.g. HIV, epilepsy, malaria): <a href="http://www.porphyria.uct.ac.za" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Porphyria South Africa</a></div></li><li class="half_rhythm"><div>Safe drug lists are available at the following website: <a href="http://www.wmic.wales.nhs.uk/specialist-services/drugs-in-porphyria/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Welsh Medicines Information Centre - Porphyria Information Service</a></div></li><li class="half_rhythm"><div>Unsafe drug lists are available at the following website: <a href="https://about.medicinescomplete.com/publication/british-national-formulary/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">British National Formulary</a> (subscription required)</div></li></ul></div><div id="aip.Evaluation_of_Relatives_at_Risk_for"><h3>Evaluation of Relatives at Risk for All Individuals with AIP</h3><p>It is appropriate to clarify the genetic status of apparently asymptomatic at-risk relatives of an individual with either overt or latent AIP so that those who are <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for an <i>HMBS</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> (and thus at increased risk of developing acute attacks of AIP) can be identified early and counseled about preventive measures and surveillance (see <a href="#aip.Prevention_of_Primary_Manifestations">Prevention of Primary Manifestations</a>, <a href="#aip.AgentsCircumstances_to_Avoid_for_All">Agents/Circumstances to Avoid</a>, and <a href="#aip.Surveillance">Surveillance</a>).</p><ul><li class="half_rhythm"><div>When the <i>HMBS</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in the family, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> is the method of choice for identification of individuals <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for an <i>HMBS</i> pathogenic variant who are thus at risk for an acute attack.</div></li><li class="half_rhythm"><div>Measurement of erythrocyte HMBS activity is less sensitive but may be useful for the few families in which an <i>HMBS</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> cannot be identified or when molecular testing is unavailable.</div></li><li class="half_rhythm"><div>Urinary porphobilinogen (PBG) excretion should not be used as it is normal in all prepubertal children with latent AIP and in at least 50% of adults.</div></li></ul><p>Note: Although acute attacks are rare before puberty, children in families with AIP should be offered testing with appropriate consent from parents or guardians in order to provide advice/education on avoidance of precipitating factors and ensure rapid diagnosis with prompt treatment should an attack occur in adolescence.</p><p>See <a href="#aip.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="aip.Pregnancy_Management"><h3>Pregnancy Management</h3><p>The majority of women with AIP have completely normal pregnancies with no clinical symptoms relating to the porphyria [<a class="bk_pop" href="#aip.REF.marsden.2010.591">Marsden &#x00026; Rees 2010</a>] despite a small chance that pregnancy could initiate or worsen porphyria symptoms.</p><p><a class="bk_pop" href="#aip.REF.toll_nes.2011.217">Toll&#x000e5;nes et al [2011]</a> reported an increased risk of perinatal loss for first-time mothers with active acute porphyria.</p><p>When a woman with AIP experiences abdominal pain, hypertension, and tachycardia during pregnancy, complications of pregnancy should be excluded before the findings are attributed to an acute attack.</p><p>Symptomatic treatment of an acute attack that occurs during pregnancy should take into account the potential for the medication to precipitate/exacerbate an acute attack of porphyria in the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> woman and the potential risk of an adverse effect of the drug on the developing fetus.</p><p>Intravenous human hemin (both available preparations) has been used for the treatment of acute attacks in pregnancy. There is limited published data on the effects of hemin infusion on the developing human fetus. <a class="bk_pop" href="#aip.REF.marsden.2010.591">Marsden &#x00026; Rees [2010]</a> published a questionnaire study in which two women treated with heme arginate during pregnancy reported delivering a total of three infants without birth defects. One of these infants was subsequently noted to have normal growth and development at age two years.</p><p>Prolonged fasting should be avoided during labor and delivery as should the use of porphyrinogenic drugs (e.g., ergometrine).</p><p><b>Note: In an obstetric emergency, no drug should be restricted if it is likely to be of major clinical benefit or is required in a life-threatening situation.</b></p><p>Stress should be minimized by providing good analgesia. Regional anesthesia, in the form of spinal or epidural anesthesia using bupivacaine, has been used without adverse effects.</p><p>See <a href="http://www.mothertobaby.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">MotherToBaby</a> for further information on medication use during pregnancy.</p></div><div id="aip.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions.</p></div></div><div id="aip.Genetic_Counseling"><h2 id="_aip_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="aip.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Acute intermittent porphyria (AIP) is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner.</p></div><div id="aip.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div class="half_rhythm">The majority of individuals diagnosed with AIP have inherited an <i>HMBS</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> from one of their parents, who may or may not be symptomatic.</div></li><li class="half_rhythm"><div class="half_rhythm">Unless a parent is already known to be <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for an <i>HMBS</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> for the pathogenic variant identified in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> should be undertaken to confirm the genetic status of the parents.</div></li><li class="half_rhythm"><div class="half_rhythm">In the rare instance that the <i>HMBS</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> cannot be detected in the leukocyte DNA of either parent, possible explanations include a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a>
<i>HMBS</i> pathogenic variant in the proband or <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> for the <i>HMBS</i> pathogenic variant in a parent*. Though theoretically possible, no instances of germline mosaicism have been reported.</div><div class="half_rhythm">* Misattributed parentage can also be explored as an alternative explanation for an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div></li><li class="half_rhythm"><div class="half_rhythm">Due to the low <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> of clinical manifestations of AIP, a significant proportion of heterozygotes are asymptomatic and the family history of many probands will appear to be negative. Therefore, an apparently negative family history cannot be confirmed unless <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> has been performed on the parents of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The risk to the sibs of the proband depends on the genetic status of the proband's parents:</p><ul><li class="half_rhythm"><div>If one of the parents of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has an <i>HMBS</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the risk to each sib of inheriting the pathogenic variant is 50%. Because clinical <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> is low (see <a href="#aip.Penetrance">Penetrance</a>), it is not possible to predict whether individuals who inherit an <i>HMBS</i> pathogenic variant will be &#x02013; or if they are symptomatic, the age of onset, severity, or type of symptoms.</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has a known <i>HMBS</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> that cannot be detected in the leukocyte DNA of either parent, the risk to sibs of inheriting a pathogenic variant is estimated to be 1% because of the theoretic possibility of parental <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> [<a class="bk_pop" href="#aip.REF.rahbari.2016.126">Rahbari et al 2016</a>].</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Each child of an individual with an <i>HMBS</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has a 50% chance of inheriting the <i>HMBS</i> pathogenic variant.</p><p><b>Other family members.</b> The risk to other family members depends on the status of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents: if a parent has the <i>HMBS</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, his or her family members are at risk.</p></div><div id="aip.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#aip.Evaluation_of_Relatives_at_Risk_for">Evaluation of Relatives at Risk</a> for information on evaluating at-risk asymptomatic family members for the purpose of early diagnosis and treatment.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk and discussion of the availability and indications for prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or at risk.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="aip.Prenatal_Testing_and_Preimplantation"><h3>Prenatal Testing and Preimplantation Genetic Testing</h3><p>Once the <i>HMBS</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-testing/">preimplantation genetic testing</a> for AIP are possible. Because clinical <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> is low, the finding of an <i>HMBS</i> pathogenic variant on prenatal testing cannot be used to predict whether an individual will become symptomatic, &#x02013; or if they do become symptomatic, the age of onset, severity, or type of symptoms.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="aip.Resources"><h2 id="_aip_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>American Porphyria Foundation (APF)</b></div><div>915 St. Elmo Avenue</div><div>Suite 200</div><div>Bethesda MD 20814</div><div><b>Phone:</b> 866-APF-3635 (toll-free); 301-347-7166</div><div><b>Email:</b> porphyrus@porphyriafoundation.com</div><div><a href="https://www.porphyriafoundation.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.porphyriafoundation.org</a></div></li><li class="half_rhythm"><div><b>British &#x00026; Irish Porphyria Network (BIPNET)</b></div><div>United Kingdom</div><div><a href="http://www.bipnet.org.uk/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.bipnet.org.uk</a></div></li><li class="half_rhythm"><div><b>British Porphyria Association</b></div><div>United Kingdom</div><div><b>Phone:</b> 0300 30 200 30</div><div><b>Email:</b> helpline@porphyria.org.uk</div><div><a href="http://www.porphyria.org.uk/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.porphyria.org.uk</a></div></li><li class="half_rhythm"><div><b>Canadian Association for Porphyria/Association Canadienne de Porphyrie</b></div><div>Canada</div><div><a href="http://canadianassociationforporphyria.ca/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.canadianassociationforporphyria.ca</a></div></li><li class="half_rhythm"><div><b>Find a Porphyria Expert</b></div><div>American Porphyria Foundation</div><div><a href="https://www.porphyriafoundation.org/for-patients/porphyria-experts/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.porphyriafoundation.org/for-patients/porphyria-experts</a></div></li><li class="half_rhythm"><div><b>My46 Trait Profile</b></div><div><a href="https://www.my46.org/trait-document?trait=Acute%20intermittent%20porphyria&#x00026;parent=Genetic%20Syndromes&#x00026;type=profile" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Acute intermittent porphyria</a></div></li><li class="half_rhythm"><div><b>National Acute Porphyria Service (NAPS)</b></div><div>United Kingdom</div><div><b>Phone:</b> +44 29 2184 7747</div><div><a href="http://www.cardiffandvaleuhb.wales.nhs.uk/national-acute-porphyria-service-naps" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.cardiffandvaleuhb.wales.nhs.uk/national-acute-porphyria-service-naps</a></div></li><li class="half_rhythm"><div><b>National Library of Medicine Genetics Home Reference</b></div><div><a href="http://ghr.nlm.nih.gov/condition=acuteintermittentporphyria;jsessionid=D4E2E078605EC9CE8599D96BB81EBC0E" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Porphyria</a></div></li><li class="half_rhythm"><div><b>Porphyria South Africa</b></div><div>South Africa</div><div><b>Phone:</b> +27 21-4066332</div><div><b>Fax:</b> +27 21-4066061</div><div><b>Email:</b> Peter.Meissner@uct.ac.za</div><div><a href="http://www.porphyria-patients.uct.ac.za/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Porphyria for Patients</a></div></li><li class="half_rhythm"><div><b>Welsh Medicines Information Centre</b></div><div><i>The Welsh Medicines Information Centre (WMIC) offers a specialist advisory service on the safe use of drugs in porphyria.</i></div><div>United Kingdom</div><div><b>Phone:</b> +44 029 2074 4298</div><div><a href="https://www.wmic.wales.nhs.uk/specialist-services/drugs-in-porphyria/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Drugs in Porphyria</a></div></li><li class="half_rhythm"><div><b>European Porphyria Network</b></div><div><b>Email:</b> contact@porphyria.eu</div><div><a href="http://porphyria.eu/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">porphyria.eu</a></div></li><li class="half_rhythm"><div><b>Swedish Porphyria Patients' Association</b></div><div>Karolinska Universitetssjukhuset</div><div>Huddinge M 96</div><div>Stockholm Stockholms Lan SE-141 86</div><div>Sweden</div><div><b>Phone:</b> +46 8 711 56 09 </div><div><b>Email:</b> porfyrisjukdomar@gmail.com</div><div><a href="http://www.porfyri.se" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.porfyri.se</a></div></li></ul></div><div id="aip.Molecular_Genetics"><h2 id="_aip_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="aip.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Acute Intermittent Porphyria: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1193/table/aip.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__aip.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_aip.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_aip.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_aip.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_aip.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_aip.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_aip.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_aip.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/3145" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>HMBS</i></a></td><td headers="hd_b_aip.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=3145" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">11q23<wbr style="display:inline-block"></wbr>​.3</a></td><td headers="hd_b_aip.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P08397" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Porphobilinogen deaminase</a></td><td headers="hd_b_aip.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/HMBS" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HMBS database</a></td><td headers="hd_b_aip.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=HMBS" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HMBS</a></td><td headers="hd_b_aip.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=HMBS[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HMBS</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="aip.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="aip.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Acute Intermittent Porphyria (<a href="/omim/176000,609806" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1193/table/aip.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__aip.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/176000" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">176000</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PORPHYRIA, ACUTE INTERMITTENT; AIP</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/609806" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">609806</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HYDROXYMETHYLBILANE SYNTHASE; HMBS</td></tr></tbody></table></div></div><div id="aip.Molecular_Pathogenesis"><h3>Molecular Pathogenesis</h3><p><i>HMBS</i> encodes a ubiquitous PBG deaminase isoform (exons 1 and 3-15) that is expressed in all tissues and an erythroid isoform (exons 2-15, with <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 2 being noncoding) that is restricted to erythroid cells [<a class="bk_pop" href="#aip.REF.grandchamp.1989.6637">Grandchamp et al 1989</a>] via alternative <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> under the control of two promoters. Common trans-acting factors may coregulate the transcription of the HMBS enzyme activity of these genes.</p><p>Porphobilinogen deaminase is the third enzyme in the heme biosynthetic pathway. It functions as a monomer localized within the cytoplasm where it catalyzes the synthesis of the linear tetrapyrrole hydroxymethlbilane from four molecules of porphobilinogen [<a class="bk_pop" href="#aip.REF.bung.2019.7932">Bung et al 2019</a>].</p><p><b>Mechanism of disease causation.</b> AIP occurs through a <a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a> mechanism. Most <i>HMBS</i> pathogenic variants are <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>/<a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, small deletions/insertions, or <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants. Larger deletions/duplications/insertions and even whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions have been reported.</p><p>A large proportion (~85%) of pathogenic variants are associated with a 50% reduction in enzyme protein in all tissues as a consequence of unstable or absent protein. The remainder of disease-associated variants (mainly <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants) result in effects on protein stability and folding, cofactor assembly, and the catalytic process. Modeling studies based on the crystallographic structure have provided important insight into these mechanisms [<a class="bk_pop" href="#aip.REF.bustad.2013.33">Bustad et al 2013</a>].</p><p>The major hypothesis proposed for the pathogenesis of the neurologic lesions that give rise to the clinical features of acute porphyria is 5-aminolevulinic acid (ALA) toxicity. The success of liver transplantation as a cure for recurrent acute attacks [<a class="bk_pop" href="#aip.REF.wahlin.2010.e18">Wahlin et al 2010</a>] and the transplant of a liver from persons with AIP into unaffected persons who then experienced acute attacks [<a class="bk_pop" href="#aip.REF.dowman.2011.571">Dowman et al 2011</a>] clearly implicate release of a hepatic neurotoxin, probably ALA, as their cause.</p><p><b><i>HMBS</i>-specific laboratory technical considerations.</b> 2% of HMBS variants recorded in HGMD are gross deletions or insertions (<a href="https://portal.biobase-international.com/hgmd/pro/gene.php?gene=HMBS" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">portal.biobase-international.com</a>, accessed 02/10/19). These will not be detected by single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> sequencing but may be identified by gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> or <a class="def" href="/books/n/gene/glossary/def-item/next-generation-sequencing/">next-generation sequencing</a>.</p><div id="aip.T.notable_hmbs_pathogenic_variants" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Notable <i>HMBS</i> Pathogenic Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1193/table/aip.T.notable_hmbs_pathogenic_variants/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__aip.T.notable_hmbs_pathogenic_variants_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_aip.T.notable_hmbs_pathogenic_variants_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th><th id="hd_h_aip.T.notable_hmbs_pathogenic_variants_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_aip.T.notable_hmbs_pathogenic_variants_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_aip.T.notable_hmbs_pathogenic_variants_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Comment [Reference]</th></tr></thead><tbody><tr><td headers="hd_h_aip.T.notable_hmbs_pathogenic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000190.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000190<wbr style="display:inline-block"></wbr>​.3</a><br /><a href="https://www.ncbi.nlm.nih.gov/protein/NP_000181.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000181<wbr style="display:inline-block"></wbr>​.2</a></td><td headers="hd_h_aip.T.notable_hmbs_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.593G&#x0003e;A</td><td headers="hd_h_aip.T.notable_hmbs_pathogenic_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.(Trp198Ter)</td><td headers="hd_h_aip.T.notable_hmbs_pathogenic_variants_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Founder variant in northern Sweden [<a class="bk_pop" href="#aip.REF.lee.1991.10912">Lee &#x00026; Anvret 1991</a>]</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd></dl></div></div></div></div></div><div id="aip.References"><h2 id="_aip_References_">References</h2><div id="aip.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="aip.REF.bonkovsky.2014.1233">Bonkovsky HL, Maddukuri VC, Yazici C, Anderson KE, Bissell DM, Bloomer JR, Phillips JD, Naik H, Peter I, Baillargeon G, Bossi K, Gandolfo L, Light C, Bishop D, Desnick RJ. Acute porphyrias in the USA: features of 108 subjects from porphyrias consortium. <span><span class="ref-journal">Am J Med. </span>2014;<span class="ref-vol">127</span>:1233–41.</span> [<a href="/pmc/articles/PMC4563803/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4563803</span></a>] [<a href="/pubmed/25016127" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25016127</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aip.REF.bung.2019.7932">Bung N, Roy A, Priyakumar UD, Bulusu G. Computational modeling of the catalytic mechanism of hydroxymethylbilane synthase. <span><span class="ref-journal">Phys Chem Chem Phys. </span>2019;<span class="ref-vol">21</span>:7932–40.</span> [<a href="/pubmed/30918925" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30918925</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aip.REF.bustad.2013.33">Bustad HJ, Vorland M, R&#x000f8;nneseth E, Sandberg S, Martinez A, Toska K. Conformational stability and activity analysis of two hydroxymethylbilane synthase mutants, K132N and V215E, with different phenotypic association with acute intermittent porphyria. <span><span class="ref-journal">Biosci Rep. </span>2013:33.</span> [<a href="/pmc/articles/PMC3738108/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3738108</span></a>] [<a href="/pubmed/23815679" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23815679</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aip.REF.cerbino.2015.946387">Cerbino GN, Gerez EN, Varela LS, Melito VA, Parera VE, Batlle A, Rossetti MV. Acute intermittent porphyria in Argentina: an update. <span><span class="ref-journal">Biomed Res Int. </span>2015;<span class="ref-vol">2015</span>:946387</span> [<a href="/pmc/articles/PMC4449928/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4449928</span></a>] [<a href="/pubmed/26075277" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26075277</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aip.REF.chen.2019">Chen B, Whatley S, Badminton M, Aarsand AK, Anderson KE, Bissell DM, Bonkovsky HL, Cappellini MD, Floderus Y, Friesema ECH, Gouya L, Harper P, Kauppinen R, Loskove Y, Mart&#x000e1;sek P, Phillips JD, Puy H, Sandberg S, Schmitt C, To-Figueras J, Weiss Y, Yasuda M, Deybach JC, Desnick RJ., International Porphyria Molecular Diagnostic Collaborative.  an evidence-based database of verified pathogenic and benign variants for the porphyrias. <span><span class="ref-journal">Genet Med. </span>2019.</span> Epub ahead of print. [<a href="/pubmed/31073229" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 31073229</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aip.REF.deybach.2011.521">Deybach JC, Puy H. Hepatocellular carcinoma without cirrhosis: think acute hepatic porphyrias and vice versa. <span><span class="ref-journal">J Intern Med. </span>2011;<span class="ref-vol">269</span>:521–4.</span> [<a href="/pubmed/21323767" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21323767</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aip.REF.dixon.2019">Dixon N, Li T, Marion B, Faust D, Dozier S, Molina A, Rudnick S, Bonkovsky HL. Pilot study of mitochondrial bioenergetics in subjects with acute porphyrias. <span><span class="ref-journal">Mol Genet Metab. </span>2019.</span> Epub ahead of print. [<a href="/pmc/articles/PMC6864263/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6864263</span></a>] [<a href="/pubmed/31153822" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 31153822</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aip.REF.dowman.2011.571">Dowman JK, Gunson BK, Bramhall S, Badminton MN, Newsome PN. Liver transplantation from donors with acute intermittent porphyria. <span><span class="ref-journal">Ann Intern Med. </span>2011;<span class="ref-vol">154</span>:571–2.</span> [<a href="/pubmed/21502660" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21502660</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aip.REF.elder.2013.849">Elder G, Harper P, Badminton M, Sandberg S, Deybach JC. The incidence of inherited porphyrias in Europe. <span><span class="ref-journal">J Inherit Metab Dis. </span>2013;<span class="ref-vol">36</span>:849–57.</span> [<a href="/pubmed/23114748" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23114748</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aip.REF.floderus.2002.288">Floderus Y, Shoolingin-Jordan PM, Harper P. Acute intermittent porphyria in Sweden. Molecular, functional and clinical consequences of some new mutations found in the porphobilinogen deaminase gene. <span><span class="ref-journal">Clin Genet. </span>2002;<span class="ref-vol">62</span>:288–97.</span> [<a href="/pubmed/12372055" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12372055</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aip.REF.gouya.2019">Gouya L, Ventura P, Balwani M, Bissell DM, Rees DC, St&#x000f6;lzel U, Phillips JD, Kauppinen R, Langendonk JG, Desnick RJ, Deybach JC, Bonkovsky HL, Parker C, Naik H, Badminton M, Stein PE, Minder E, Windyga J, Bruha R, Cappellini MD, Sardh E, Harper P, Sandberg S, Aarsand AK, Andersen J, Alegre F, Ivanova A, Talbi N, Chan A, Querbes W, Ko J, Penz C, Liu S, Lin T, Simon A, Anderson KE. EXPLORE: A prospective, multinational, natural history study of patients with acute hepatic porphyria with recurrent attacks. <span><span class="ref-journal">Hepatology. </span>2019.</span> Epub ahead of print. [<a href="/pubmed/31512765" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 31512765</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aip.REF.grandchamp.1989.6637">Grandchamp B, Picat C, de Rooij F, Beaumont C, Wilson P, Deybach JC, Nordmann Y. A point mutation G----A in exon 12 of the porphobilinogen deaminase gene results in exon skipping and is responsible for acute intermittent porphyria. <span><span class="ref-journal">Nucleic Acids Res. </span>1989;<span class="ref-vol">17</span>:6637–49.</span> [<a href="/pmc/articles/PMC318356/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC318356</span></a>] [<a href="/pubmed/2789372" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2789372</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aip.REF.hessels.2004.19">Hessels J, Voortman G, van der Wagen A, van der Elzen C, Scheffer H, Zuijderhoudt FM. Homozygous acute intermittent porphyria in a 7-year-old boy with massive excretions of porphyrins and porphyrin precursors. <span><span class="ref-journal">J Inherit Metab Dis. </span>2004;<span class="ref-vol">27</span>:19–27.</span> [<a href="/pubmed/14970743" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14970743</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aip.REF.hift.2011.158">Hift RJ, Thunell S, Brun A. Drugs in porphyria: From observation to a modern algorithm-based system for the prediction of porphyrogenicity. <span><span class="ref-journal">Pharmacol Ther. </span>2011;<span class="ref-vol">132</span>:158–69.</span> [<a href="/pubmed/21704073" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21704073</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aip.REF.innala.2011.538">Innala E, Andersson C. Screening for hepatocellular carcinoma in acute intermittent porphyria: a 15-year follow-up in northern Sweden. <span><span class="ref-journal">J Intern Med. </span>2011;<span class="ref-vol">269</span>:538–45.</span> [<a href="/pubmed/21198994" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21198994</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aip.REF.lee.1991.10912">Lee JS, Anvret M. Identification of the most common mutation within the porphobilinogen deaminase gene in Swedish patients with acute intermittent porphyria. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>1991;<span class="ref-vol">88</span>:10912–5.</span> [<a href="/pmc/articles/PMC53042/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC53042</span></a>] [<a href="/pubmed/1961762" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1961762</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aip.REF.lenglet.2018.1164">Lenglet H, Schmitt C, Grange T, Manceau H, Karboul N, Bouchet-Crivat F, Robreau AM, Nicolas G, Lamoril J, Simonin S, Mirmiran A, Karim Z, Casalino E, Deybach JC, Puy H, Peoc'h K, Gouya L. From a dominant to an oligogenic model of inheritance with environmental modifiers in acute intermittent porphyria. <span><span class="ref-journal">Hum Mol Genet. </span>2018;<span class="ref-vol">27</span>:1164–73.</span> [<a href="/pubmed/29360981" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29360981</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aip.REF.marsden.2010.591">Marsden JT, Rees DC. A retrospective analysis of outcome of pregnancy in patients with acute porphyria. <span><span class="ref-journal">J Inherit Metab Dis. </span>2010;<span class="ref-vol">33</span>:591–6.</span> [<a href="/pubmed/20567908" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20567908</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aip.REF.peoch.2018">Peoc'h K, Manceau H, Karim Z, Wahlin S, Gouya L, Puy H, Deybach JC. Hepatocellular carcinoma in acute hepatic porphyrias: A Damocles Sword. <span><span class="ref-journal">Mol Genet Metab. </span>2018.</span> Epub ahead of print. [<a href="/pubmed/30413387" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30413387</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aip.REF.pischik.2009.72">Pischik E, Kauppinen R. Neurological manifestations of acute intermittent porphyria. <span><span class="ref-journal">Cell Mol Biol (Noisy-le-grand). </span>2009;<span class="ref-vol">55</span>:72–83.</span> [<a href="/pubmed/19268005" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19268005</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aip.REF.puy.2010.924">Puy H, Gouya L, Deybach J-C. Porphyrias. <span><span class="ref-journal">Lancet. </span>2010;<span class="ref-vol">375</span>:924–37.</span> [<a href="/pubmed/20226990" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20226990</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aip.REF.rahbari.2016.126">Rahbari R, Wuster A, Lindsay SJ, Hardwick RJ, Alexandrov LB, Turki SA, Dominiczak A, Morris A, Porteous D, Smith B, Stratton MR, Hurles ME, et al.  Timing, rates and spectra of human germline mutation. <span><span class="ref-journal">Nat Genet. </span>2016;<span class="ref-vol">48</span>:126–33.</span> [<a href="/pmc/articles/PMC4731925/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4731925</span></a>] [<a href="/pubmed/26656846" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26656846</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aip.REF.sardh.2019.549">Sardh E, Harper P, Balwani M, Stein P, Rees D, Bissell DM, Desnick R, Parker C, Phillips J, Bonkovsky HL, Vassiliou D, Penz C, Chan-Daniels A, He Q, Querbes W, Fitzgerald K, Kim JB, Garg P, Vaishnaw A, Simon AR, Anderson KE. Phase I trial of an RNA interference therapy for acute intermittent porphyria. <span><span class="ref-journal">N Engl J Med. </span>2019;<span class="ref-vol">380</span>:549–58.</span> [<a href="/pubmed/30726693" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30726693</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aip.REF.schulenburgbrand.2017.99">Schulenburg-Brand D, Gardiner T, Guppy S, Rees DC, Stein P, Barth J, Felicity Stewart M, Badminton M. An audit of the use of gonadorelin analogues to prevent recurrent acute symptoms in patients with acute porphyria in the United Kingdom. <span><span class="ref-journal">JIMD Rep. </span>2017;<span class="ref-vol">36</span>:99–107.</span> [<a href="/pmc/articles/PMC5680288/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5680288</span></a>] [<a href="/pubmed/28220410" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28220410</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aip.REF.solis.2004.1764">Solis C, Martinez-Bermejo A, Naidich TP, Kaufmann WE, Astrin KH, Bishop DF, Desnick RJ. Acute intermittent porphyria: studies of the severe homozygous dominant disease provides insights into the neurologic attacks in acute porphyrias. <span><span class="ref-journal">Arch Neurol. </span>2004;<span class="ref-vol">61</span>:1764–70.</span> [<a href="/pubmed/15534187" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15534187</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aip.REF.stein.2017.527">Stein PE, Badminton MN, Rees DC. Update review of the acute porphyrias. <span><span class="ref-journal">Br J Haematol. </span>2017;<span class="ref-vol">176</span>:527–38.</span> [<a href="/pubmed/27982422" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27982422</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aip.REF.stewart.2012.976">Stewart MF. Review of hepatocellular cancer, hypertension and renal impairment as late complications of acute porphyria and recommendations for patient follow-up. <span><span class="ref-journal">J Clin Pathol. </span>2012;<span class="ref-vol">65</span>:976–80.</span> [<a href="/pubmed/22851509" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22851509</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aip.REF.tchernitchko.2017.1924">Tchernitchko D, Tavernier Q, Lamoril J, Schmitt C, Talbi N, Lyoumi S, Robreau AM, Karim Z, Gouya L, Thervet E, Karras A, Puy H, Pallet N. A variant of peptide transporter 2 predicts the severity of porphyria-associated kidney disease. <span><span class="ref-journal">J Am Soc Nephrol. </span>2017;<span class="ref-vol">28</span>:1924–32.</span> [<a href="/pmc/articles/PMC5461799/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5461799</span></a>] [<a href="/pubmed/28031405" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28031405</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aip.REF.toll_nes.2011.217">Toll&#x000e5;nes MC, Aarsand AK, Sandberg S. Excess risk of adverse pregnancy outcomes in women with porphyria: a population-based cohort study. <span><span class="ref-journal">J Inherit Metab Dis. </span>2011;<span class="ref-vol">34</span>:217–23.</span> [<a href="/pmc/articles/PMC3026662/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3026662</span></a>] [<a href="/pubmed/20978938" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20978938</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aip.REF.wahlin.2010.e18">Wahlin S, Harper P, Sardh E, Andersson C, Andersson DE, Ericzon BG. Combined liver and kidney transplantation in acute intermittent porphyria. <span><span class="ref-journal">Transpl Int. </span>2010;<span class="ref-vol">23</span>:e18–21.</span> [<a href="/pubmed/20028496" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20028496</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aip.REF.wang.2018.193">Wang B, Rudnick S, Cengia B, Bonkovsky HL. Acute hepatic porphyrias: review and recent progress. <span><span class="ref-journal">Hepatol Commun. </span>2018;<span class="ref-vol">3</span>:193–206.</span> [<a href="/pmc/articles/PMC6357830/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6357830</span></a>] [<a href="/pubmed/30766957" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30766957</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aip.REF.whatley.2009.1406">Whatley SD, Mason NG, Woolf JR, Newcombe RG, Elder GH, Badminton MN. Diagnostic strategies for autosomal dominant acute porphyrias: retrospective analysis of 467 unrelated patients referred for mutational analysis of the HMBS, CPOX, or PPOX gene. <span><span class="ref-journal">Clin Chem. </span>2009;<span class="ref-vol">55</span>:1406–14.</span> [<a href="/pubmed/19460837" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19460837</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aip.REF.woolf.2017.188">Woolf J, Marsden JT, Degg T, Whatley S, Reed P, Brazil N, Stewart MF, Badminton M. Best practice guidelines on first-line laboratory testing for porphyria. <span><span class="ref-journal">Ann Clin Biochem. </span>2017;<span class="ref-vol">54</span>:188–98.</span> [<a href="/pubmed/27555665" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27555665</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aip.REF.zheng.2018.e11665">Zheng X, Liu X, Wang Y, Zhao R, Qu L, Pei H, Tuo M, Zhang Y, Song Y, Ji X, Li H, Tang L, Yin X. Acute intermittent porphyria presenting with seizures and posterior reversible encephalopathy syndrome: Two case reports and a literature review. <span><span class="ref-journal">Medicine (Baltimore). </span>2018;<span class="ref-vol">97</span>:e11665</span> [<a href="/pmc/articles/PMC6133578/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6133578</span></a>] [<a href="/pubmed/30200061" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30200061</span></a>]</div></li></ul></div></div><div id="aip.Chapter_Notes"><h2 id="_aip_Chapter_Notes_">Chapter Notes</h2><div id="aip.Author_History"><h3>Author History</h3><p>Michael Badminton, PhD, FRCPath (2013-present)<br />Shigeru Sassa, MD, PhD; The Rockefeller University (2005-2010)<br />Stig Thunell, MD, PhD; Karolinska University Hospitall Huddinge (2010-2013)<br />Sharon Whatley, PhD, FRCPath (2013-present)</p></div><div id="aip.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>5 December 2019 (bp) Comprehensive update posted live</div></li><li class="half_rhythm"><div>7 February 2013 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>1 September 2011 (cd) Revision: addition of links to Rare Diseases Clinical Research Network Porphyrias Consortium and Registry (Management)</div></li><li class="half_rhythm"><div>23 March 2010 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>27 September 2005 (me) Review posted live</div></li><li class="half_rhythm"><div>3 January 2005 (ss) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1193</span><span class="label">PMID: <a href="/pubmed/20301372" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301372</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/amrf/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/adams-oliver/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1193&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1193/?report=reader">PubReader</a></li><li><a href="/books/NBK1193/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1193" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1193" style="display:none" title="Cite this Page"><div class="bk_tt">Whatley SD, Badminton MN. Acute Intermittent Porphyria. 2005 Sep 27 [Updated 2019 Dec 5]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1193/pdf/Bookshelf_NBK1193.pdf">PDF version of this page</a> (488K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#aip.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#aip.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#aip.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#aip.Genetically_Related_Allelic_Disorder" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#aip.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#aip.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#aip.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#aip.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#aip.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#aip.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#aip.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=3145[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">HMBS</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1459930" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1459930" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1459930" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1459930" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/23409300" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Variegate Porphyria</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Variegate Porphyria<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Singal AK, Anderson KE. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/23236641" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hereditary Coproporphyria</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hereditary Coproporphyria<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Wang B, Bissell DM. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301512" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hypokalemic Periodic Paralysis</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hypokalemic Periodic Paralysis<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Weber F, Lehmann-Horn F. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24006547" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ornithine Transcarbamylase Deficiency</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ornithine Transcarbamylase Deficiency<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Lichter-Konecki U, Caldovic L, Morizono H, Simpson K. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/18271838" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Hemodialysis: a therapeutic option for severe attacks of acute intermittent porphyria in developing countries.</a><span class="source">[Hemodial Int. 2008]</span><div class="brieflinkpop offscreen_noflow">Hemodialysis: a therapeutic option for severe attacks of acute intermittent porphyria in developing countries.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Prabahar MR, Manorajan R, Sathiyakumar D, Soundararajan P, Jayakumar M. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Hemodial Int. 2008 Jan; 12(1):34-8. </em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301372" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301372" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e041376dde0891169bf5632">Acute Intermittent Porphyria - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Acute Intermittent Porphyria - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T20:57:10-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal104&amp;ncbi_phid=CE8B636EE040BEA10000000003240141&amp;ncbi_session=CE8B636EE0413751_0804SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1193%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1193&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1193/&amp;ncbi_pagename=Acute Intermittent Porphyria - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8B636EE0413751_0804SID /projects/books/PBooks@5.22 portal104 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>